Physician profile
Todd Williams
NPI 1790985463
$4,185.80
in general payments reported to CMS, 2019-2025
21 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $378 · 2023: $771 · 2024: $1,306 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.74 |
| Education | $391.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,131.48 | 2021-2025 | |
| Janssen Biotech, INC. | $725.41 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $487.91 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $373.10 | 2021-2025 | Blu-U, Ilumya, Odomzo |
| Lilly USA, LLC | $361.17 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $350.58 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $148.19 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $107.34 | 2023-2024 | Sotyktu |
| Incyte Corporation | $82.25 | 2022-2023 | Opzelura |
| Amgen INC. | $80.86 | 2021-2024 | Otezla |
| Pfizer INC. | $63.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.38 | 2023 | Spevigo |
| Genzyme Corporation | $40.56 | 2021 | |
| Organon LLC | $33.74 | 2025 | |
| Novo Nordisk INC | $28.71 | 2025 | Ozempic |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $26.82 | 2023 | Poteligeo |
| Teva Pharmaceuticals USA, INC. | $23.31 | 2024 | Simlandi |
| Almirall LLC | $22.50 | 2022 | |
| Galderma Laboratories, L.P. | $22.10 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $17.43 | 2023 | |
| Hill Dermaceuticals, INC. | $9.90 | 2023 | Tolak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.